Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Table 3 Relationships between the European Organization for Research and Treatment of Cancer Quality of Life-Core 30-item and its related factors at three time periods (S1, S2, and S3)

Characteristic	Global health status			Physical functioning			Role functioning			Emotional functioning			Cognitive functioning			Social functioning
	S1	S2	S3	S1	S2	S3	S1	S2	S3	S1	S2	S3	S1	S2	S3	S1	S2	S3
Age	-0.55	-0.96	-0.01	-0.61	-2.291	-1.01	-0.79	-0.83	-2.261	-0.49	1.08	-0.81	-0.7	-0.5	-1.11	-1.21	-2.071	-1.99
Sex	-0.67	0.14	-1.11	-0.03	-0.18	-0.07	-1.33	-0.01	-1.43	0.31	0.33	-0.15	-0.44	0.6	-0.07	-0.56	-0.24	-0.69
ECOG	1.21	-0.84	0.33	2.782	0.56	2.071	3.873	-1.02	1.49	1.29	0.05	0.01	1.92	1.79	-0.69	-0.47	-1.56	-1.04
HTN	-1.23	-0.7	-0.44	-0.56	-0.84	-0.29	-1.47	-0.16	-0.05	-0.3	0.52	-0.11	0.41	-1.07	-0.4	-1.32	-1.23	-0.32
DM	-0.05	-0.41	-2.03	-0.06	-0.32	-2.07	-0.7	0.48	-0.97	-0.48	0.7	-1.2	0.96	0.55	-0.83	-0.77	-1.41	-1.58
HBV	0.24	0.24	1.03	1.39	0.96	0.76	-0.12	0.4	-0.03	-0.07	1.13	0.08	0.19	1.55	0.5	-2.711	-0.54	-0.07
HCV	1.2	0.18	-0.75	0.95	0.36	0.08	-0.49	0.32	0.28	0.17	1.34	0.96	-0.62	-0.15	0.92	-0.41	0.59	-0.07
Primary or recurrent tumor	-0.98	-0.39	-1.04	-2.03	-0.54	-0.82	-1.78	-0.73	-1.32	-0.79	0.94	0.24	-0.15	1.48	0.74	-1.52	0.58	-0.39
Primary cancera	1.36	1.43	1.36	0.48	0.46	0.48	0.43	0.6	0.43	0.63	0.36	0.63	1.12	0.59	1.12	1	0.93	1
Previous definitive surgery	-1.33	-0.83	-1.16	-1.25	-1.12	-1.14	-0.81	-0.66	-0.51	-0.63	0.92	0.27	-0.78	-0.07	-0.26	-1.31	0.24	-0.4
Previous systemic chemotherapy	-1.57	-1.86	-2.151	-0.99	-0.9	-1.1	-1.37	-1.05	-1.52	-0.89	0.43	-0.93	0.29	0.45	-1	-1.37	-0.71	-1.99
PCIb	-0.05	-0.02	0.1	-0.15	-0.12	-0.13	-0.15	-0.12	-0.05	-0.22	-0.04	0.04	-0.11	0.03	-0.01	-0.01	-0.05	-0.05
CCa	0.93	1.14	0.48	1.03	1.07	0.37	0.53	1.07	0.29	1.45	0.06	0.35	0.38	0.53	0.3	0.72	0.85	0.13
Duration of peritonectomy (min)b	-0.06	-0.18	0.11	0.18	-0.21	0.05	0.09	-0.37	-0.01	0.01	0.04	0.09	-0.14	0.04	-0.03	-0.09	-0.04	0.05
LOS (days)b	-0.13	0.14	-0.03	-0.02	0.1	-0.07	0	0.06	-0.12	-0.01	0.2	0.03	-0.26	0.13	-0.05	0.09	0.18	0.07
Surgical method	0.64	-0.01	0.47	0.54	0.3	0.65	1.18	0.72	0.11	2.111	1.6	1.14	0.65	2.872	1.4	2.872	0.72	-0.22
HIPEC regimen	-1.11	-0.63	-0.52	-0.39	0.89	2.561	-0.15	0.07	-0.12	-0.04	-0.35	0.63	-0.66	0.44	1.93	-0.54	-1.38	0.39
HIPEC indicationa	0.95	0.15	1.16	1.34	0.44	0	0.39	0.47	0.01	0.93	0.11	0.15	0.02	0.22	0.08	1.54	1.39	0.15
Duration of HIPEC (mins)	0.82	0.44	0.37	1.01	-0.7	-2.131	0.6	0.48	0.42	0.62	1.28	-0.04	0.01	-1.46	-2.431	0.84	1.38	-0.1
Post-op complicationsa	0.62	0.54	2.05	0.69	0.88	0.19	0.51	0.99	0.67	0.4	0.34	1.34	2.24	1.51	1.25	0.48	1.15	2.61
PGSGA	1.84	0.49	1.08	0.79	0.14	1.28	-1.27	-0.78	0.9	1.16	-0.19	-0.44	1.25	0.42	1.2	-0.55	0.74	0.6
MDASI-T
SSb	-0.483	-0.34	-0.7	-0.38	-0.46	-0.52	-0.3	-0.453	-0.483	-0.342	-0.493	-0.643	-0.543	-0.2	-0.723	-0.24	-0.331	-0.613
DILb	-0.543	-0.493	-0.693	-0.433	-0.633	-0.66	-0.473	-0.603	-0.693	-0.433	-0.433	-0.723	-0.392	-0.281	-0.673	-0.533	-0.523	-0.783

^aF coefficients;

^br coefficients;

¹P < 0.05;

²P < 0.01;

³P < 0.001.

BMI: Body mass index; CC: Completeness of cytoreduction; DIL: Degree of interference with life; DM: Diabetes mellitus; ECOG: Eastern Cooperative Oncology Group performance status; HBV: hepatitis B; HCV: hepatitis C; HTN: Hypertension; PCI: Peritoneal carcinomatosis index; PGSGA: Patient-Generated Subjective Global Assessment; SS: Symptom severity; LOS: Length of hospital stay; MDASI-T: MD Anderson Symptom Inventory-Taiwan version. S1: The first visit before CRS/HIPEC; S2: The second visit, the first outpatient follow-up visit after CRS/HIPEC; S3: The third visit, the outpatient visit 3 mo after CRS/HIPEC.